These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 25667801)

  • 1. Effective treatment of eisoptrophobia with duloxetine: a case report.
    Pitchot W
    Prim Care Companion CNS Disord; 2014; 16(5):. PubMed ID: 25667801
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
    Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
    Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.
    Tomita T; Yasui-Furukori N; Kaneko S
    Clin Neuropharmacol; 2013; 36(5):175-6. PubMed ID: 24045610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine-associated tachycardia.
    Stevens DL
    Ann Pharmacother; 2008 Oct; 42(10):1511-3. PubMed ID: 18728105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
    Bellows BK; Dahal A; Jiao T; Biskupiak J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):153-64. PubMed ID: 22509775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: fulminant hepatic failure involving duloxetine hydrochloride.
    Hanje AJ; Pell LJ; Votolato NA; Frankel WL; Kirkpatrick RB
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):912-7. PubMed ID: 16797245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
    Wielage R; Bansal M; Wilson K; Klein R; Happich M
    Spine (Phila Pa 1976); 2013 May; 38(11):936-46. PubMed ID: 23250234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study.
    Di Rezze S; Frasca V; Inghilleri M; Durastanti V; Cortese A; Giacomelli E; Millefiorini E
    Clin Neuropharmacol; 2012; 35(5):231-4. PubMed ID: 22751087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N; Schennach R; Riedel M; Möller HJ
    Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute massive pulmonary thromboembolism due to acute intoxication by duloxetine: a case report.
    Mari F; Gualco B; Rensi R; Bertol E
    Cardiovasc Toxicol; 2012 Sep; 12(3):258-62. PubMed ID: 22351288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of duloxetine in pregnancy and lactation.
    Briggs GG; Ambrose PJ; Ilett KF; Hackett LP; Nageotte MP; Padilla G
    Ann Pharmacother; 2009 Nov; 43(11):1898-902. PubMed ID: 19809008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial.
    Ramos MG; Hara C; Rocha FL
    Int J Neuropsychopharmacol; 2009 Sep; 12(8):1081-8. PubMed ID: 19250561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
    Fava M; Detke MJ; Balestrieri M; Wang F; Raskin J; Perahia D
    J Psychiatr Res; 2006 Jun; 40(4):328-36. PubMed ID: 16678205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine.
    Englisch S; Fritzinger M; Zink M
    Clin Neuropharmacol; 2008; 31(5):307-9. PubMed ID: 18836353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine in the treatment of burning mouth syndrome refractory to conventional treatment: A case report.
    Kim YD; Lee JH; Shim JH
    J Int Med Res; 2014 Jun; 42(3):879-83. PubMed ID: 24743872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics.
    Mori M; Koide T; Imanishi Y; Matsui Y; Matsuda T
    Indian J Pharmacol; 2014; 46(6):657-9. PubMed ID: 25538343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid onset of syndrome of inappropriate antidiuretic hormone secretion induced by duloxetine in an elderly type 2 diabetic patient with painful diabetic neuropathy.
    Kamei S; Kaneto H; Tanabe A; Irie S; Hirata Y; Shimoda M; Kohara K; Mune T; Kaku K
    J Diabetes Investig; 2015 May; 6(3):343-5. PubMed ID: 25969720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
    Wu WY; Wang G; Ball SG; Desaiah D; Ang QQ
    Chin Med J (Engl); 2011 Oct; 124(20):3260-8. PubMed ID: 22088518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study.
    Mihaylova B; Pitman R; Tincello D; van der Vaart H; Tunn R; Timlin L; Quail D; Johns A; Sculpher M
    Value Health; 2010 Aug; 13(5):565-72. PubMed ID: 20456715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.